2-(4-(3-(hexyl(methyl)amino)propyl)-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl)acetic acid

ID: ALA4570905

PubChem CID: 155562960

Max Phase: Preclinical

Molecular Formula: C20H29N3O4

Molecular Weight: 375.47

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCCCN(C)CCCn1c(=O)c(=O)n(CC(=O)O)c2ccccc21

Standard InChI:  InChI=1S/C20H29N3O4/c1-3-4-5-8-12-21(2)13-9-14-22-16-10-6-7-11-17(16)23(15-18(24)25)20(27)19(22)26/h6-7,10-11H,3-5,8-9,12-15H2,1-2H3,(H,24,25)

Standard InChI Key:  INEQWSFZUBMHFL-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 28  0  0  0  0  0  0  0  0999 V2000
   19.0537   -9.9551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7676  -10.3600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.4773   -9.9479    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.1913  -10.3528    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.4732   -9.1265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9010   -9.9406    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6108  -10.3456    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3205   -9.9334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0344  -10.3384    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7442   -9.9262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3440  -10.3673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6300   -9.9623    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.2129   -9.1474    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.2151   -9.9697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9253  -10.3791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9209   -8.7346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6268   -9.1434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3301   -8.7339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3288   -7.9199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6183   -7.5171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9179   -7.9248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5005   -8.7356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4994   -7.9143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7870   -7.5066    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.2107   -7.5048    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.5039  -10.3795    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.9309  -11.2004    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  3  5  1  0
  4  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  1 11  1  0
 11 12  1  0
 12 17  1  0
 12 15  1  0
 16 13  1  0
 13 14  1  0
 14 15  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 16  1  0
 13 22  1  0
 22 23  1  0
 23 24  1  0
 23 25  2  0
 14 26  2  0
 15 27  2  0
M  END

Alternative Forms

  1. Parent:

    ALA4570905

    ---

Associated Targets(Human)

KDM5A Tchem Lysine-specific demethylase 5A (893 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 375.47Molecular Weight (Monoisotopic): 375.2158AlogP: 2.15#Rotatable Bonds: 11
Polar Surface Area: 84.54Molecular Species: ZWITTERIONHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 3.38CX Basic pKa: 9.79CX LogP: -0.60CX LogD: -0.60
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.48Np Likeness Score: -0.81

References

1. Miyake Y, Itoh Y, Hatanaka A, Suzuma Y, Suzuki M, Kodama H, Arai Y, Suzuki T..  (2019)  Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.,  27  (6): [PMID:30745098] [10.1016/j.bmc.2019.02.006]

Source